Trial Profile
A phase I/II study of numonafide for the treatment of refractory acute myelogenous leukemia (AML)
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2015
Price :
$35
*
At a glance
- Drugs Numonafide (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2015 New trial record
- 01 Apr 2015 Panther Biotechnology plans to file an IND application in the 4th quarter of 2015 and intends to initiate this study by the end of 2015.